CRNA Circio Holding ASA

OSL · NO · Healthcare · Biotechnology · circio.com

10.88NOK+1.68%Mkt Cap: 291.04M $P/E: —Today

Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three cli…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap291.04M USD

Enterprise Value224.30M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-4.29M USD

Revenue/Share—

Last Price10.88 NOK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees10

CountryNO

SectorHealthcare

IndustryBiotechnology

ISINNO0013033795

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-38.08

EV/Revenue—

P/S—

P/B5.66

EPS (TTM)-0.37

EPS (Forward)0.00

52W Range

0.590068% of range15.70

52W High15.70 NOK

52W Low0.5900 NOK

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE367.49%

ROA-426.80%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-4.28M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-0.80%

Net Debt-50.39M USD

Net Debt/EBITDA8.55

Balance Sheet

Debt/Equity-0.67

Current Ratio20.42

Quick Ratio20.42

Book Value/Sh1.89 NOK

Cash/Share1.96 NOK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 NOK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:30

Split DateOct 4, 2023

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.290.97M

Float218.85M

Insiders30.07%

Institutions3.76%

Technical

SMA 5010.66 (+2.0%)

SMA 2007.029 (+54.8%)

Beta-1.11

S&P 52W Chg14.58%

Avg Vol (30d)11.18M

Avg Vol (10d)5.06M

Technical Indicators

RSI (14)46.5

MACD-0.1292

MACD Signal0.0601

MACD Hist.-0.1893

BB Upper13.85 NOK

BB Middle11.60 NOK

BB Lower9.355 NOK

BB Width38.72%

ATR (14)0.8077 NOK

Vol Ratio (20d)0.40x